• English
  • Deutsch
  • Log In
    Password Login
    Research Outputs
    Fundings & Projects
    Researchers
    Institutes
    Statistics
Repository logo
Fraunhofer-Gesellschaft
  1. Home
  2. Fraunhofer-Gesellschaft
  3. Artikel
  4. HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma
 
  • Details
  • Full
Options
October 23, 2025
Journal Article
Title

HO-1197 as a Multifaceted Therapeutic: Targeting the Cell Cycle, Angiogenesis, Metastasis, and Tumor Immunity in Hepatocellular Carcinoma

Abstract
Hepatocellular carcinoma (HCC) is the most prevalent primary malignancy of the liver. Characterized by rapid progression and poor overall survival rates, HCC requires effective and streamlined treatment regimens. It predominantly occurs in East Asia and sub-Saharan Africa, where it has historically been managed with herbal formulas. We previously observed that the herbal formula HO-1089 exerts potent anti-HCC effects both in vitro and in vivo. In this study, we investigated the anticancer efficacy and mechanisms of HO-1197, a reconstituted herbal formulation derived from HO-1089. HO-1197 selectively inhibited the viability of HCC cell lines without hepatotoxicity and demonstrated superior anticancer activity compared with both HO-1089 and sorafenib. Mechanistically, HO-1197 induced apoptosis and G2/M arrest through reactive oxygen species-mediated DNA damage, independent of p53 status. Transcriptomic analysis revealed downregulation of mitosis-related genes, particularly those regulated by FOXM1, a key driver of HCC proliferation and metastasis. HO-1197 suppressed FOXM1 expression and nuclear translocation, reducing its downstream targets and diminishing angiogenic and metastatic potential. Furthermore, HO-1197 modulated the tumor immune microenvironment by promoting pro-inflammatory macrophage polarization and enhancing natural killer cell-mediated cytotoxicity. HO-1197 exhibited potent antitumor efficacy, and combination therapy with HO-1197 and sorafenib exhibited synergistic effects in both two-dimensional and immune-activated multicellular spheroid models. These findings suggest that HO-1197 is a promising multifunctional therapeutic candidate with antitumor, antiangiogenic, antimetastatic, and immunomodulatory properties. Its combination with sorafenib may offer effective treatment for HCC. HO-1197, which demonstrated strong efficacy, is a novel herbal medicine developed by H&O Biosis and is referred to as an Integrated Natural Medicine.
Author(s)
Song, Yeonhwa
Institut Pasteur Korea, Advanced Biomedical Research Lab
Lee, Seungeun
Institut Pasteur Korea, Advanced Biomedical Research Lab
Heo, So-Won
Institut Pasteur Korea, Advanced Biomedical Research Lab
Spohn, Juliane  
Fraunhofer-Institut für Keramische Technologien und Systeme IKTS  
Schmiedel, Dominik  
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Heo, Taemoo
Institut Pasteur Korea, Advanced Biomedical Research Lab
Kim, Sanghwa
Institut Pasteur Korea, Advanced Biomedical Research Lab
Park, Jongmin
H&O Biosis Co., Ltd.
Seo, Haeng Ran
Institut Pasteur Korea, Advanced Biomedical Research Lab
Journal
International journal of molecular sciences  
Project(s)
NA
Funder
National Research Foundation of Korea  
Open Access
File(s)
Download (3.88 MB)
Rights
CC BY 4.0: Creative Commons Attribution
DOI
10.3390/ijms262110329
10.24406/publica-6152
Additional link
Full text
Language
English
Fraunhofer-Institut für Keramische Technologien und Systeme IKTS  
Fraunhofer-Institut für Zelltherapie und Immunologie IZI  
Keyword(s)
  • hepatocellular carcinoma (HCC)

  • cell cycle arrest

  • FOXM1

  • angiogenesis

  • metastasis

  • immune modulation

  • Cookie settings
  • Imprint
  • Privacy policy
  • Api
  • Contact
© 2024